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Summary The role of glutathione (GSH) in resistance to cisplatin (CDDP) was studied in a human small cell
lung carcinoma cell line (GLC4) and a CDDP-resistant subline (GLC4-CDDP). In addition to studying the
steady state of GSH, the kinetics of this defence system were also studied via the monitoring of the GSH
status of the cells under continuous pressure of CDDP. GLC4-CDDP maintained its elevated GSH level
whereas GLC4 (under pressure ofCDDP) quickly synthesised GSH to about twice its intitial level, correspond-
ing with 80% of the GSH level of GLC4-CDDP. D,L-buthionine-S,R-sulphoximine (BSO) was used to analyse
the role of GSH in resistance to CDDP. Pretreatment with BSO (48 h, 50 tAM, GSH not detectable) increased
the CDDP-induced cytotoxicity 2.8-fold in GLC4-CDDP and 1.7-fold in GLC4. In GLC4 no changes in the
amount of platinum (Pt) bound to DNA could be observed after GSH depletion. Changes in formation of
interstrand cross-links or the main Pt-containing intrastrand cross-link in digested DNA, the Pt-GG adduct,
were also not observed. In GSH depleted GLC4-CDDP cells, an increase in the amount of Pt bound to DNA
and in the Pt-GG adduct was observed. Pretreatment with BSO substantially reduced the repair of Pt bound
to DNA in both cell lines. We conclude that an increased GSH level and GSH synthesis capacity were
demonstrated in CDDP resistant cells. The observations after BSO treatment suggest two roles for GSH in
CDDP resistance, namely that of a cytosolic elimination resulting in less DNA platination and a nuclear effect
on the formation and repair of DNA platinum adducts.
The development of acquired resistance to the useful anti-
neoplastic drug cisplatin (CDDP) is a major limitation to the
drug's clinical use. Several mechanisms responsible for this
resistance to CDDP including reduced membrane permea-
bility, enhanced drug detoxification, changes at the level of
DNA adduct formation and increased efficiency of DNA
repair have been previously reported (Teicher et al., 1987;
Richon et al., 1987; Waud, 1987; Kraker & Moore, 1988;
Andrews et al., 1988; Hamilton et al., 1985; Hromas et al.,
1987; Behrens et al., 1987; Eastman & Schulte, 1988).
There is growing evidence that glutathione (GSH), the
major cellular non-protein thiol, may play an important role
in cellular resistance to several chemotherapeutic agents
(Arrick & Nathan, 1984; Green et al., 1984; Tan et al., 1987;
Evans et al., 1987; Hospers et al., 1988). Its roles in CDDP
resistance, however, remains controversial. CDDP is
sufficiently electrophilic to react directly with GSH (Eastman,
1987), resulting in a decrease in the level of drug metabolites
that can react with critical intracellular targets such as DNA.
An increased GSH level, therefore, could protect cells in an
early stage of exposure to CDDP. The consumption of GSH
in this reaction then affects the GSH production cycle. Since
the effects of this burden on GSH economy are unknown we
chose to study the possibility that resistant cells might handle
their GSH status in a way different from that of sensitive
cells. It has also been reported that CDDP resistance may be
mediated by quenching of DNA-platinum mono adducts by
GSH (Micetich et al., 1983) favoured by an increase in
cellular GSH content.
To analyse the role of GSH in resistance to CDDP we
used D,L-buthionine-S,R-sulphoximine (BSO) to block GSH-
synthesis and studied a number of critical events after
exposure to CDDP. This article reports on research aimed at
evaluating: cellular and nuclear GSH, CDDP-induced
cytotoxicity, cellular platinum (Pt) levels, the amount of Pt
bound to DNA, the number of interstrand cross-links, the
Pt-GG adduct content (the main Pt-containing intrastrand
cross-link in digested DNA) and the repair of the amount of
Pt bound to DNA in a CDDP sensitive and resistant human
small cell lung cancer cell line.
Materials and methods
Chemicals
CDDP was provided by Bristol Myers SAE, Madrid, Spain.
RPMI 1640 medium was obtained from Gibco, Paisley, UK.
Fetal calf serum was obtained from Flow Lab, Irvine, UK.
GSH, 1-chloro-2,4-dinitrobenzene (CDNB), 5,5-dithiobis (2-
nitrobenzoic acid), ethylene glycol-bis(P-amino ethyl
ether)N,N,N',N'-tetra acetic acid (EGTA), Triton X-100, (3-
[4,5-dimethyl-thiazol-2y1]2,5-diphenyltetrazoliumbromide) (MTT)
and DNAse I were obtained from Sigma (St Louis, MO),
dimethyl sulphoxide and Proteinase K from Merck (Darm-
stadt, FRG), BSO from Chemalog (South Plainfield, NJ),
nuclease P1 from Boehringer (Mannheim, FRG), ethidium
bromide from Serva (Heidelberg, FRG), and 3H-thymidine
(1 mCi ml-') from New England Nuclear (Boston, MA).
Cell lines
GLC4, a human small cell lung cancer cell line and a CDDP
resistant subline, GLC4-CDDP, characterised before by
Hospers et al. (1988), were cultured in RPMI 1640 medium
with 10% heat-inactivated fetal calf serum at 37°C, 5% CO2.
GLC4-CDDP was cultured under constant challenge of a
monthly dose of 75 lgml' CDDP. During the period in
which the experiments for this study were performed, doub-
ling times were 16 h and 28 h for GLC4 and GLC4-CDDP,
respectively. Total GSH levels were 4.6 ± 0.5 and
11.5 ± 2.4ytg mg-' protein, respectively in GLC4 and GLC4-
CDDP (mean ± s.d.).
BSO treatment
Cells were cultured as described above for 48 h in the
presence of 50jiM BSO. At 48 h, GSH was no longer detect-
able in both cell lines (detection limit: 50 ng), without growth
delay or loss of viability. Compared to control cultures no
recovery time after BSO pretreatment was needed, after a
culture period of 4 days (MTT-assay, described below) no
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indication of growth delay or loss of viability could be
observed.
GSH
Cells in the logarithmic phase of growth were harvested 4
days after passage. Cells were washed with ice-cold phos-
phate buffered saline (PBS) and resuspended in a relevant
concentration. All measurements were performed under Vmax
conditions. For cellular GSH determination, cells were
resuspended in ice-cold 5% trichloroacetic acid (TCA), mixed
vigorously and centrifuged at 4°C (5 min, 10,000g). The
supernatant was assayed for total GSH through enzyme
recycling under conditions similar to those described by
Tietze (1969). The detection limit was 0.1 I g mg'- protein.
For nuclear GSH, nuclei were isolated according to the
method described by Pommier et al. (1983). Cells were
washed twice with ice-cold PBS and resuspended in a 1/10
volume nucleus buffer (150 mM NaCI, 1 mM KH2PO4, 5 mM
MgCl2, 1 mM EGTA and 0.1 mM dithiothreitol, pH 6.4) at
4°C. Then 9/10 volume of nucleus buffer containing 0.3%
Triton X-100 at 4°C was added and the mixture was
incubated for 10min at 4°C. The nuclei were pelleted by
centrifugation and resuspended in nucleus buffer at 4°C.
Nuclei were examined microscopically after staining with
trypan blue to confirm the recovery of nuclei and the absence
of cytoplasm. Nuclei were then resuspended in ice-cold 5%
TCA, mixed vigorously and centrifuged at 4°C (15 min,
10,000g). The supernatant was assayed for total GSH as
described above.
For protein determination the Lowry assay was used
(Lowry et al., 1951). All measurements were performed on a
Zeiss PMQ spectrophotometer. A minimum of three separate
experiments were performed.
Dynamics ofGSH
The effect of continuous exposure to 5.8 JIM CDDP (the dose
which inhibits the cell survival of GLC4 by 50% (IC50) after
I h of incubation) on the GSH content of GLC4 and GLC4-
CDDP was measured by sampling for GSH and protein
determination at different time intervals varying up to 5 h.
Also, the effect of continuous exposure to 32 JIM CDDP (the
IC50 of GLC4-CDDP after 1 h incubation) on the GSH con-
tent of GLC4-CDDP was measured. A minimum of two
separate experiments were performed in duplicate.
Drug sensitivity assay
The Microculture tetrazolium assay (MTA) used in this
research is based on the cellular reduction of MTT by the
mitochondrial dehydrogenase of viable cells to a blue forma-
zan product which can be measured spectrophotometrically
(Carmichael et al., 1987). Before the assays were
performed, the linear relationship of cell number to MTT
formazan crystal formation was checked and cell growth
studies were performed. Cells were in the exponential phase
of growth at the moment of testing and at least two to three
cell divisions should have taken place. Care was taken to
select one day (at day 4) to test cell survival for both cell
lines. This was possible when we started with 5,000 and
15,000 cells for GLC4 and GLC4-CDDP, respectively.
Incubation of 5,000 cells per well for GLC4 and 15,000
cells per well for GLC4-CDDP proceeded in a total volume of
0.1 ml culture medium with CDDP for 4 h, in 96-well culture
plates (Nunc, Gibco, Paisley, UK). For experiments after
48 h BSO incubation, the cells were exposed to CDDP for
4 h in culture medium without BSO. After the CDDP
incubation, cells were washed three times by removing the
medium after centrifugation of the microtitre plate (10 min,
180g) followed by addition of fresh medium. After a culture
period of 4 days, 20 1l of MTT-solution (5 mg MTT ml-'
PBS) was added to each well for 3.5 h. Thereafter, the plates
were centrifuged (30min, 180g) and the supernatant was
carefully aspirated, so as not to disturb the formazan cry-
stals. Dimethyl sulphoxide 100% (200 .l) was used to dis-
solve the formazan crystals. The plate was immediately read
at 520 nm using a scanning microtitre well spectrophotometer
(Titertek Multiskan, Flow Lab, Irvine, UK). The percentage
cell survival was calculated by dividing the mean of the test
sample by the mean of the untreated sample. Controls con-
sisted of media without cells (background extinction) and
cells incubated in wells with medium instead of the drug. At
least three separate experiments were performed in quadru-
plicate at each tested concentration.
Pt determinations
The amount of platinum (Pt) was determined with a model
1275 atomic absorption spectrophotometer (AAS) equipped
with a model GTA-95 graphite tube atomizer and an
autosampler (Varian Techtron Pty Ltd, Mulgrave, Victoria,
Australia). A solution of CDDP in the solvent used in each
experiment was used for calibration. The Pt detection limit
was 2.5 pmol.
Cellular Pt measurements
For cellular Pt measurements, 5 x 106 cells were incubated
for 4 h with CDDP concentrations ranging from 83 to
500gM. After three washes with PBS at 4°C, pellets were
dissolved in 0.5 ml 65% HNO3 in an oven at 70°C for 2 h.
The amount of Pt was determined as described above. A
minimum of three separate experiments were performed at
each CDDP incubation concentration.
Total Pt bound to DNA
The amount of Pt bound to the DNA was measured after
treating 5 x 107 cells with CDDP concentrations ranging
from 83 to 500gM for 4 h. The cells were washed three times
with PBS at 4°C, and the DNA was isolated by using the
technique described by Fichtinger-Schepman et al. (1987).
Briefly, a phenol extraction and ethanol precipitation was
followed by RNase treatment. The remaining proteins were
extracted by chloroform/iso-amylalcohol. After isolation, the
DNA was dissolved 1 N HCI. The DNA content was esti-
mated by absorption at 260 nm; the amount of Pt in the
sample was estimated by AAS as described by Roberts and
Fraval (1980). At least three independent experiments were
performed at each CDDP concentration.
Pt-GG adduct
The Pt-GG was measured by AAS after treating the cells
with CDDP for 4 h. DNA was isolated from 5 x 10' cells
after CDDP treatment and subsequent washing with PBS, as
described earlier. After digestion of DNA, to 350 p1l DNA
solution in distilled H20, 39 p1 of buffer was added (100 mM
Tris-HCI, 40 mm MgCI2, 1 mM Na2EDTA) supplemented
with 9.4 p11 Omm ZnSo4, 14p1 DNAse I (3,000 U ml-') and
39itl Nuclease P1 (1 mgml-'), the mixture was incubated at
37°C overnight after which 25 1l proteinase K (18 mg ml-')
was added. This was followed by incubation for another 2 h
at 37C. Subsequently, the digest was heated for 5 min at
100C and, after the addition of 20.3 iLl 1 M Tris-HCI, centri-
fuged in an Eppendorf centrifuge for 2 min), the adduct was
separated by anion-exchange column chromatography on the
Mono Q HR 5/5 column having a particle size of 10gM (Pharmacia, Uppsala, Sweden) according to the method des-
cribed by Fichtinger-Schepman et al. (1987). The Pt-GG
adduct content in the eluate fractions were determined by Pt
measurements with AAS. The total DNA content of a sam-
ple was estimated by absorption at 260 nm (Fichtinger-
Schepman et al., 1985). At least three independent
experiments were performed at each CDDP concentration.74 C. MEIJER et al.
DNA interstrand cross-links (ISC)
Cells were incubated for 4 h with CDDP concentrations
ranging from 83 to 500gM and washed with PBS at 4°C
three times. The pellets were subsequently resuspended and
divided into two parts. The amount of ISC formed was
measured with the ethidium bromide fluorescence assay, as
described by de Jong et al. (1986). After lysation for 15 h and
the addition of the ethidium bromide, the DNA in one part
of each sample was denatured by boiling followed by rapid
cooling. The other part was kept at room temperature. The
fluorescence of both parts was measured in a Kontron spec-
trofluorometer (excitation 525 nm, emission 580 nm). The
fluorescence in the denatured part is related to the amount of
ISC formed. The fluorescence in the other part is related to
the total amount of DNA present in that particular sample.
Repair ofDNA-Pt
The removal of the amount of Pt bound to DNA was
measured after incubating 108 cells per sample for 4 h with
33 gM CDDP (the maximal tolerable dose of CDDP without
inducing cell toxicity at t = 22 h of the repair period). This
procedure was followed by harvesting cells for total Pt-DNA
binding. After CDDP treatment, half of the sample (repair
t = 0 h) was washed three times with ice-cold PBS, pelleted
by centrifugation and frozen. The other sample was washed
twice with medium (37°C) and resuspended in fresh medium
for a repair period of 22 h after which the cells were washed,
pelleted and frozen as just above. At least three separate
experiments, each in duplicate, were performed.
Correctionfor dilution by DNA synthesis
Since the repair of the amount of Pt bound to DNA was
quantified per mg of isolated DNA, correction for dilution
by DNA synthesised during the 22 h post-treatment incu-
bated period was carried out according to the method de-
scribed by Bedford et al. (1988). Cells were labelled for 44 h
with 20nCiml1' 3H-thymidine followed by 4h in isotope-
free medium. Cells were then exposed for 4 h to 33 LM
CDDP, as described previously, and harvested either
immediately or after 22 h. DNA was extracted by heating the
cell pellets at 70°C for 1 h in 1 N perchloric acid. Radio-
activity was determined in 200jul aliquots of supernatant and
the DNA content of the remainder was estimated spectro-
photometrically as described above. The dilution factor was
calculated as the specific activity of DNA at 22 h divided by
the specific activity of DNA at 0 h. The apparent amount of
Pt bound to DNA at 22 h divided by the dilution factor gave
the amount of Pt bound to DNA.
Statistics
Statistical significance was determined with the unpaired
Student's t test and for the BSO experiments with the paired
Student's t test. P values <0.05 were considered significant.
Results
Survival curves of GLC4 and GLC4-CDDP after 50jM BSO
for 48 h showed an increased CDDP induced cytotoxicity
after 4 h of CDDP treatment (Figure 1). IC5o values were
1.0IM and 221M for GLC4 and GLC4-CDDP respectively
and decreased to 0.6 tM and 7.8gM respectively. BSO
modulated CDDP survival in the sensitive cell line by a
factor of 1.7 and in the CDDP resistant cell line by a factor
of 2.8. Dose modifying factors (DMF) were calculated at the
ICIO, IC20, ..., IC90 for both cell lines to confirm a
significantly higher BSO modulating effect on the CDDP
induced cytotoxicity in GLC4-CDDP compared to GLC4.
DMF, obtained from the separate survival curves, were
1.90 ± 0.63 (n = 21) and 3.03 ± 1.51 (n = 26) in GLC4 and
GLC4-CDDP respectively (P <0.0025).
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Figure 1 Effect of pretreatment of GLC4 (0 0) and GLC4-
CDDP (@ 0) with 50 AM BSO for 48 h on CDDP induced
cytotoxicity, after 4 h incubation with CDDP, as measured by
MTA, without BSO ( ) and following pretreatment with BSO
(---) (n > 4, bars = s.e.m.). For GLC4 significantly different
values were observed at 0.25jiM, P <0.0005; at 0.51M,
P <0.0005; at 1.0JLM, P <0.0005; at 5.01M, P <0.025, and at
10i1M, P <0.0005. For GLC4-CDDP at 1.0pM, P <0.05; at
5.0J1M, P <0.0005; at l011M, P <0.0005; at 501M, P <0.0005;
at 100IM, P<0.0005; and at 25011M, P<0.025.
Nuclear GSH contents were 89 ± 12 ng mg-' cellular pro-
tein and 235 ± 138 ngmg-' cellular protein (mean ± s.d.,
n = 3) in GLC4 and GLC4-CDDP respectively (P <0.05).
The elevated nuclear GSH in GLC4-CDDP compared to
GLC4 is proportional to the elevated cellular GSH in GLC4-
CDDP compared to GLC4.
Figure 2 shows the effect of continuous exposure to 5.8l4M
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Figure 2 Effect of continuous exposure to 5.8lM CDDP on the
GSH content of GLC4 (0) and GLC4-CDDP (G) and the effect
of continuous exposure to 32l4M CDDP on the GSH content of
GLC4-CDDP (0) (n = 2, in duplicate).ROLE OF GLUTATHIONE IN CISPLATIN RESISTANCE 75
CDDP on the GSH content of GLC4 and GLC4-CDDP, and
the effect of continuous exposure to 32ltM CDDP on the
GSH content of GLC4-CDDP. Continuous exposure to
CDDP led to an increase in GSH content in GLC4. The
GSH in these cells was doubled after 5 h and contained 80%
of the amount normally (without CDDP exposure) present in
GLC4-CDDP. A short period of increase of the GSH level
was noted in GLC4-CDDP followed by a steady state at
70-90% of the initial GSH level at both 5.8 and 32tLM
CDDP.
No difference in the cellular Pt content between GLC4 and
GLC4-CDDP was observed after correction for cellular pro-
tein or cellular volume (Hospers et al., 1988). The pretreat-
ment ofcells with BSO did not alter the cellular Pt content in
GLC4 and GLC4-CDDP after 4 h CDDP treatment as
measured by AAS (data not shown).
The amount of Pt-DNA binding was significantly lower in
GLC4-CDDP as compared to GLC4. The effect of pretreat-
ment with BSO on the Pt-DNA binding after 4 h CDDP
treatment is shown in Figure 3. Following BSO pretreatment,
an increased Pt-DNA binding for GLC4-CDDP was seen
whereas the Pt-DNA binding in GLC4 remained the same. In
GLC4-CDDP a reduced number of ISC was observed as
compared to GLC4. Figure 4 shows the effect of pretreatment
with BSO on the ISC formation. Although an increase in ISC
seemed to appear in GLC4-CDDP after BSO pretreatment,
no significant change in formation could be confirmed. The
initial decreased formation of ISC in the resistant cell line
when compared to the sensitive line could be eliminated. The
effect of pretreatment with BSO on the formation of the
Pt-GG adduct is shown in Figure 5. A significant increase in
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Pt-GG adduct formation (2.6-fold) after pretreatment with
BSO was observed in GLC4-CDDP whereas the Pt-GG
adduct formation after pretreatment with BSO remained the
same for GLC4.
Table I shows the repair capacity of GLC4 and GLC4-
CDDP after incubation for 4 h with 33 t4M CDDP followed
by a drug-free culture period of 22 h. Both GLC4 and GLC4-
CDDP showed a significant reduction in the amount of Pt
bound to DNA after the 22 h drug-free culture period.
Pretreatment with 50tLM BSO for 48 h annihilated this repair
in both cell lines.
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Figure 4 Effect of pretreatment of GLC4 (0 0) and GLC4-
CDDP (0 0) with 50JAM BSO for 48 h on the ISC forma-
tion after 4 h incubation with CDDP, without BSO ( ) and
following BSO pretreatment (- -) (n > 6, bars = s.e.m.).
Significantly different values were observed for GLC4-CDDP ver-
sus GLC4 at all tested concentrations: at 83JAM, P <0.005; at
167IM, P <0.005; at 333JM, P <0.025; and at 500 M,
P <0.0005. No significant changes were observed in either cell
line following BSO treatment.
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Figure 3 Effect of pretreatment of GLC4 (0 O) and GLC4-
CDDP (0 0) with 50JAM BSO for 48 h on the Pt-DNA
binding after 4 h incubation with CDDP, without BSO (
and following BSO treatment (--- ) (n > 3, bars = s.e.m.).
Significantly different values were observed for GLC4-CDDP ver-
sus GLC4 at all tested concentrations: at 83 JAM, P <0.05; at
167JAM, P<0.01; at 333JAM, P<0.0025; and at 5OOJAM,
P <0.0025. Significantly different values were observed for
GLC4-CDDP versus GLC4-CDDP + BSO: at 333JAM, P<0.05;
and at 500JAM, P <0.05. Significantly different values for GLC4-
CDDP + BSO versus GLC4 were only observed at 83 JM,
P<0.01; and at 333yIM, P<0.05.
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Figure 5 Effect of pretreatment of GLC4 (0 0) and GLC4-
CDDP (0 0) with 50JAM BSO for 48 h on the formation of
the Pt-GG adduct after 4 h incubation with CDDP, without BSO
( ) and following BSO pretreatment (---) (n > 3, bars =
s.e.m.). Significantly different values for GLC4-CDDP versus
GLC4-CDDP + BSO were observed at 167JAM, P <0.025; at
33311M, P<0.0125; and at 5001AM, P<0.05. A significantly
different value for GLC4-CDDP+ BSO versus GLC4 was
observed at 333JiM, P<0.05.- l76 C. MEIJER et al.
Table I Repair of Pt bound to DNA, after 4 h exposure to 33gM
CDDP
t (h) fmol Ptpg' DNA
GLC4 0 475 ± 84a
22 380 47b
GLC4-CDDP 0 289+ 65c
22 168 + 82cf
GLC4 + BSO 0 451 46h
22 420 + 43d,h
GLC4-CDDP + BSO 0 283 + 107g.h
22 261 + 102d,g,h
aMean ± s.d., n = 3, in duplicate. bp <0.025, t = Oh versus
t =22h. CP<O.01, t =Oh versus t =22h. dNot significant, t =Oh
versus t = 22 h. eCp <0.0025 GLC4-CDDP t = 0 h versus GLC4
t =0 h fP <0.0005 GLC4-CDDP t = 22 h versus GLC4 t = 22 h.
gP <0.005 GLC4-CDDP + BSO t = Oh versus GLC4 + BSO t = Oh.
GLC4-CDDP + BSO t = 22 h versus GLC4 + BSO t = 22 h. hNS
GLC4 t =Oh versus GLC4+ BSO t =Oh. GLC4 t = 22h versus
GLC4 + BSO t = 22 h. GLC4-CDDP t =0 h versus GLC4-CDDP +
BSO t = Oh. GLC4-CDDP t =22 h versus GLC4-CDDP + BSO
t = 22 h.
Discussion
Given the sulphydryl reactive properties of CDDP, altera-
tions in cellular thiol content may be a defence mechanism
generated in CDDP resistant cells. GSH, the main non-
protein thiol present in cells, has been shown to be an
important determinant of the sensitivity of cells to a wide
variety of drugs including cytostatic agents (Arrick &
Nathan, 1984). Elevated levels of GSH have been associated
with drug-resistant phenotypes developed in cells exposed to
a number of electrophilic drugs (Hamilton et al., 1985; Green
et al., 1984; Tan et al., 1987; Evans et al., 1987). Moreover,
cells with elevated levels of GSH also appeared to be resist-
ant to CDDP (Richon et al., 1987; Waud, 1987; Hamilton et
al., 1985; Hromas et al., 1987; Behrens et al., 1987). How-
ever, when BSO is used to deplete GSH levels, the effect on
CDDP induced cytotoxicity varied in the different studies. In
the cell lines used in this study, the CDDP resistant subline
GLC4-CDDP had a 2.5-fold increase in GSH content as
compared to the CDDP sensitive cell line. Exposure of the
cells to BSO reduced the cellular GSH content to a non-
detectable level in both cell lines and increased the CDDP
induced cytotoxicity. This is in agreement with the findings of
Hamilton et al. (1985) and Hromas et al. (1987). In other
studies, however, no effect of BSO on CDDP-induced
cytotoxicity was found (Teicher et al., 1987; Richon et al.,
1987).
The exact mechanism by which GSH influences CDDP
cytotoxicity is not yet completely clear. CDDP can be inacti-
vated by direct binding to the sulphydryl moiety of GSH,
thereby preventing the drug from reaching the critical DNA.
This cytosolic inactivation should take place during the
limited time prior to reaction with DNA.
The steady state of GSH is generally used to express the
capacity of this defence system, although the kinetics of the
GSH status should give the more dynamic representation of
the continuous availability of this defence. In the present
study the GSH status was depicted under continuous pres-
sure of CDDP. GLC4-CDDP was able to maintain its
elevated GSH level under pressure of both 5.8 and 32tLM
CDDP suggesting an enhanced GSH biosynthetic capacity in
GLC4-CDDP. GLC4 showed a fast synthesis of GSH under
pressure of 5.8tLM CDDP. After continuous incubation for
5 h with CDDP, the GSH level reached about twice its own
original level, which corresponds to 80% of the GSH level of
GLC4-CDDP (Figure 2). In the resistant cells, however, more
GSH was available throughout the observation period. It is
evident that exposure to CDDP can increase the amount of
GSH (or can induce GSH synthesis) in some cells. Thus,
treatment with BSO and subsequent exposure to CDDP
might not lead to unmeasurably low levels of GSH in such
cells.
No change in cellular Pt content in both cell lines was
measured following CDDP exposure to BSO pretreated and
control cells, thus eliminating an effect of BSO on membrane
permeability.
The role of GSH at the nuclear level is still unclear.
Eastman (1987) showed that GSH can react in vitro with
monofunctional adducts of platinated DNA and prevent
them from rearranging to form toxic bifunctional adducts.
The formation and protective role of this GSH-adduct is,
however, still unclear.
Only small amounts of GSH could be detected in the
nuclei of GLC4 and GLC4-CDDP. The elevation of nuclear
GSH in GLC4-CDDP as compared to GLC4 is in proportion
to the increased cellular GSH content of this cell line. Since
some leakage of GSH can be assumed to occur from the
nuclei during the isolation procedure, the nuclear GSH
values are probably underestimated. However, Edgren and
Revesz (1987) also detected less than 1% of the total GSH in
the nuclei of Chinese hamster V79-379A cells. GSH depletion
by BSO was also demonstrated by them to be more efficient
in whole cells than in isolated nuclei for a period varying in
length up to 18 h. In the present study no GSH could be
detected in the nuclei of either GLC4 and GLC4-CDDP after
a 48 h pretreatment with BSO.
ISC have been reported to be enhanced after BSO-induced
GSH depletion in human leukaemia cells insensitive to
activated cyclophosphamide (Crook et al., 1986) as well as
human melanoma cells, which generally have a high degree
ofinherent resistance to bifunctional alkylating agents (Hans-
son et al., 1988). An effect of BSO on the induction of sister
chromatid exchanges has also been published (Evans et al.,
1987). In this study, neither changes in the amount of Pt
bound to DNA after GSH depletion, nor changes in the
formation of ISC or Pt-GG adducts were observed in GLC4.
In GSH depleted GLC4-CDDP cells, however, an increase in
the amount of Pt bound to DNA was found. The main
Pt-containing intrastrand cross-link in digested DNA, the
Pt-GG adduct, also increased after GSH depletion. The
difference in formation of ISC between GLC4 and GLC4-
CDDP was annihilated by pretreatment with BSO (Figures
3-5).
Lai et al. (1989) recently described that, aside from the
generally considered BSO effects on alkylating agents related
to GSH reduction, BSO treatment partially inhibited DNA
repair after CDDP damage in an ovarian cancer cell line with
in vitro induced resistance to CDDP, as measured by un-
scheduled DNA synthesis.
In the present study, the repair of the amount of Pt bound
to DNA was assayed at an incubation concentration of
33ILM CDDP for 4 h. Under these conditions, repair of the
amount of Pt bound to DNA could be observed in both
GLC4 and GLC4-CDDP, a capacity which was earlier de-
scribed to be only operational in the GLC4-CDDP line with
a resistance factor of 11 (Hospers et al., 1990), most prob-
ably due to the treatment schedule (t = 2 h compared to
t =4 h) in combination with a high CDDP concentration
(especially for GLC4) used in the previous study. After GSH
depletion, both cell lines were unable to repair the CDDP
induced amount of Pt bound to DNA. The elimination ofthe
quenching of monofunctional DNA adducts by GSH, result-
ing from BSO pretreatment, may be an explanation for the
loss of repair capacity in both cell lines.
A disparity in concentrations used for the various
parameters due to the detection limit for Pt as measured by
AAS was unavoidable. Taking this into account, we conclude
that an increased GSH level and GSH synthesis capacity was
demonstrated in CDDP resistant cells. The observations after
BSO treatment, namely the 2.6-fold increase in the CDDP
induced cytotoxicity in GLC4-CDDP, suggest two roles for
GSH in CDDP resistance, namely a cytosolic elimination
resulting in less DNA platination, and a more pronounced
nuclear effect on the formation and repair of DNA platinum
adducts. The still remaining thirteen-fold resistance after
BSO treatment in these CDDP resistant cell lines, however,
should dispute the 'relative' importance of this GSHROLE OF GLUTATHIONE IN CISPLATIN RESISTANCE 77
mediated CDDP resistance in perspective with the other
mechanisms that are operative in this line, such as a
decreased total DNA platination, a decreased Pt-GG adduct
formation, a decreased ISC formation and/or a more efficient
DNA repair.
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